Nogron (Temozolomide)

Temozolomide, the active ingredient in Nogron, is an alkylating agent presented as an oral formulation for oral use. It treats glioblastoma multiforme and anaplastic astrocytoma in adult patients. It is indicated for use in combination with radiotherapy as part of standard treatment protocols for high‑grade gliomas.

GNH USA supplies Nogron as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to Good Distribution Practice and provides regulatory documentation to support import and clinical use. It ensures timely delivery to qualified healthcare facilities worldwide.

Temozolomide is employed in the management of malignant brain tumors, particularly high‑grade gliomas.

Glioblastoma multiforme: improves overall survival when used with radiotherapy Anaplastic astrocytoma: prolongs progression‑free survival as part of combined chemoradiation High‑grade glioma (unspecified): serves as standard adjuvant chemotherapy following surgical resection Recurrent glioblastoma: provides a therapeutic option in selected patients

Temozolomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Fatigue - Constipation - Headache

Serious or Rare Side Effects: - Myelosuppression leading to neutropenia or thrombocytopenia - Severe infections such as sepsis - Hepatic toxicity with elevated transaminases

When prescribing Temozolomide, clinicians should observe several safety measures to minimise risk. - Monitor blood counts: perform regular complete blood count assessments to detect myelosuppression. - Assess liver function: check hepatic enzymes before and during therapy. - Avoid concurrent myelosuppressive agents: do not combine with other chemotherapy that depresses bone marrow. - Use effective contraception: pregnancy must be avoided during treatment and for several months after. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Temozolomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with warfarin: may increase bleeding risk. - Combination with other alkylating agents: can exacerbate bone‑marrow toxicity. - Administration of live vaccines: immunosuppression may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Enzyme‑inducing antiepileptic drugs (e.g., carbamazepine, phenytoin): may lower temozolomide plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure and toxicity.